AVITA Medical Management
Management criteria checks 2/4
AVITA Medical's CEO is Jim Corbett, appointed in Sep 2022, has a tenure of 2.17 years. total yearly compensation is $2.07M, comprised of 30.2% salary and 69.8% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth $116.01K. The average tenure of the management team and the board of directors is 1.8 years and 6.1 years respectively.
Key information
Jim Corbett
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 30.2% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.8yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Oct 04
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jul 18Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?
Jun 18Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding
Apr 12AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%
Feb 02The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%
Oct 20Avita Medical appoints James Corbett as CEO
Sep 29AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal
Sep 12Avita's burn therapy Recell gets insurance coverage in Japan following approval
Sep 01AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M
Aug 11AVITA Medical Is Interesting, But Not Just Yet
Dec 21AVITA Medical reports preliminary Q2 revenue in-line with consensus
Jan 12AVITA: COVID-19's Impact
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$2m | US$625k | -US$35m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$2m | US$157k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$30m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$256k | n/a | -US$25m |
Compensation vs Market: Jim's total compensation ($USD2.07M) is about average for companies of similar size in the US market ($USD2.14M).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
CEO
Jim Corbett (66 yo)
2.2yrs
Tenure
US$2,068,675
Compensation
Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 2.2yrs | US$2.07m | 0.033% $ 115.9k | |
| Chief Financial Officer | 1.4yrs | US$2.18m | no data | |
| Senior Vice President of Global Operations | 1.8yrs | no data | no data | |
| Senior Vice President of Scientific & Medical Affairs | less than a year | no data | no data | |
| Investor Relations Executive | no data | no data | no data | |
| Chief Legal & Compliance Officer and Corporate Secretary | less than a year | no data | no data | |
| Senior Vice President of Global Marketing & Strategy | 6.3yrs | no data | no data | |
| Senior Vice President of Human Resources | 1.8yrs | no data | no data | |
| Senior Vice President of Product Development & Program Management | 1.8yrs | no data | no data | |
| Senior Vice President of Quality Assurance & Regulatory Affairs | 1.8yrs | no data | no data | |
| Senior Vice President of U.S. Commercial Sales | less than a year | no data | no data |
1.8yrs
Average Tenure
Experienced Management: RCEL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 3.3yrs | US$2.07m | 0.033% $ 115.9k | |
| Independent Non-Executive Director | 3.3yrs | US$211.12k | 0.11% $ 385.5k | |
| Independent Non-Executive Director | 12.1yrs | US$199.87k | 0.079% $ 275.0k | |
| Founder and Member of Clinical Advisory Board | 8.8yrs | US$29.80k | no data | |
| Independent Non-Executive Chairman | 10.3yrs | US$234.69k | 0.16% $ 576.0k | |
| Independent Non-Executive Director | 1.6yrs | US$369.11k | 0.075% $ 261.9k | |
| Independent Non-Executive Director | 1.6yrs | US$364.94k | 0.037% $ 128.5k | |
| Independent Non-Executive Director | 8.8yrs | US$195.28k | 0.10% $ 363.2k |
6.1yrs
Average Tenure
67yo
Average Age
Experienced Board: RCEL's board of directors are considered experienced (6.1 years average tenure).